<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="RSOB200174TB1" orientation="portrait" position="float">
 <label>Table 1.</label>
 <caption>
  <p>CP dosage during previously encountered coronavirus outbreaks along with the novel coronavirus.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <colgroup span="1">
   <col align="left" span="1"/>
   <col align="left" span="1"/>
   <col align="left" span="1"/>
   <col align="left" span="1"/>
   <col align="left" span="1"/>
  </colgroup>
  <thead valign="bottom">
   <tr>
    <th align="left" rowspan="1" colspan="1">disease and the causative agent</th>
    <th align="left" rowspan="1" colspan="1">CP dose (volume)</th>
    <th align="left" rowspan="1" colspan="1">antibody titre</th>
    <th align="left" rowspan="1" colspan="1">summarized findings</th>
    <th align="left" rowspan="1" colspan="1">references</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="1" colspan="1">SARS caused by SARS-CoV</td>
    <td rowspan="1" colspan="1">279 ± 127 (160–640) ml
     <break/>200 ml
     <break/>500 ml
     <break/>2 units of 250 ml each (total 500 ml)
    </td>
    <td rowspan="1" colspan="1">NA
     <break/>NA
     <break/>IgG: &gt;640
     <break/>NA
    </td>
    <td rowspan="1" colspan="1">—overall, 80 patients received CP; ten patients died
     <break/>—CP at approximately 14 (7–30) days following the onset of symptoms
     <break/>—good clinical outcome; by day 22, 33 patients were discharged from the hospital
     <break/>—improved outcome with early administration of CP
     <break/>—no adverse events
    </td>
    <td rowspan="1" colspan="1">[
     <xref rid="RSOB200174C49" ref-type="bibr">49</xref>,
     <xref rid="RSOB200174C67" ref-type="bibr">67</xref>,
     <xref rid="RSOB200174C87" ref-type="bibr">87</xref>–
     <xref rid="RSOB200174C89" ref-type="bibr">89</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">MERS caused by MERS-CoV</td>
    <td rowspan="1" colspan="1">four transfusions of CP to three patients; volumes not stated
     <break/>2 units (250–350 ml/unit)
     <break/>250 ml
    </td>
    <td rowspan="1" colspan="1">1:40 to 1:80
     <break/>NA
     <break/>NA
    </td>
    <td rowspan="1" colspan="1">—all three patients survived, questionable benefits
     <break/>—feasibility study to evaluate the ratio of convalescent donors having antibodies against MERS-CoV
     <break/>—case report of one patient
     <break/>—TRALI observed
    </td>
    <td rowspan="1" colspan="1">[
     <xref rid="RSOB200174C67" ref-type="bibr">67</xref>,
     <xref rid="RSOB200174C90" ref-type="bibr">90</xref>–
     <xref rid="RSOB200174C92" ref-type="bibr">92</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">COVID-19 caused by SARS-CoV-2</td>
    <td rowspan="1" colspan="1">200 ml
     <break/>two consecutive transfusions of 200–250 ml (400 ml total)
    </td>
    <td rowspan="1" colspan="1">neutralizing antibody titre: &gt;1:640
     <break/>ELISA anti-SARS-CoV-2—antibody titre: &gt;1:1000
     <break/>neutralizing antibody titre: &gt;1:40
    </td>
    <td rowspan="1" colspan="1">—uncontrolled, 10 severely ill patients, CP at 16.5 (11.0–19.3) days; recovery of all patients; no significant adverse effect
     <break/>—uncontrolled five critically ill cases, CP at 10–22 days after admission; recovery of all patients
    </td>
    <td rowspan="1" colspan="1">[
     <xref rid="RSOB200174C53" ref-type="bibr">53</xref>,
     <xref rid="RSOB200174C93" ref-type="bibr">93</xref>]
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
